BR9407869A - Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose - Google Patents

Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose

Info

Publication number
BR9407869A
BR9407869A BR9407869A BR9407869A BR9407869A BR 9407869 A BR9407869 A BR 9407869A BR 9407869 A BR9407869 A BR 9407869A BR 9407869 A BR9407869 A BR 9407869A BR 9407869 A BR9407869 A BR 9407869A
Authority
BR
Brazil
Prior art keywords
osteoporosis
treatment
combination
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BR9407869A
Other languages
English (en)
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9407869A publication Critical patent/BR9407869A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9407869A 1993-10-19 1994-10-18 Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose BR9407869A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (1)

Publication Number Publication Date
BR9407869A true BR9407869A (pt) 1996-10-29

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407869A BR9407869A (pt) 1993-10-19 1994-10-18 Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose

Country Status (16)

Country Link
EP (1) EP0813414A4 (pt)
JP (1) JPH09504525A (pt)
KR (1) KR960705575A (pt)
CN (1) CN1136278A (pt)
AU (1) AU8083694A (pt)
BG (1) BG100517A (pt)
BR (1) BR9407869A (pt)
CA (1) CA2173333A1 (pt)
CZ (1) CZ109196A3 (pt)
FI (1) FI961681A7 (pt)
HU (1) HUT75224A (pt)
LV (1) LV11432B (pt)
NO (1) NO961536L (pt)
PL (1) PL314003A1 (pt)
SK (1) SK49796A3 (pt)
WO (1) WO1995011029A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
EP0828754B1 (en) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
CA2234817A1 (en) * 1995-10-27 1997-05-01 Mandana Asgharnejad Wet granulation formulation of a growth hormone secretagogue
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
US6242199B1 (en) 1995-12-13 2001-06-05 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
BR9709499A (pt) * 1996-05-31 1999-08-10 Novo Nordisk As Processo para prevenção ou tratamento de osteoporose e de perturbações relacionamas uso de um componente de hormónio do crescimento uso de uma composição com uma ação de anti-reabsorção sobre os ossos e produtos
AU4993497A (en) * 1996-10-25 1998-05-22 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
EP1112282A4 (en) 1998-08-10 2002-10-31 Merck & Co Inc RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AU2686899A (en) * 1998-08-18 2000-03-14 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CN1372468A (zh) * 1999-06-02 2002-10-02 宝洁公司 羟乙磷酸二钠口服制剂
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
DE60111574T2 (de) 2001-01-23 2006-05-11 Gador S.A. Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
KR20070046929A (ko) 2004-08-19 2007-05-03 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조절제
RU2007124373A (ru) 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
JP2009521483A (ja) 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1987034B1 (en) 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101500565A (zh) 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
AU2007284548A1 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2051715A2 (en) 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
US7973162B2 (en) 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
KR20210018323A (ko) 2018-06-06 2021-02-17 매사추세츠 인스티튜트 오브 테크놀로지 진핵 세포에서의 번역을 위한 원형 rna
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状ｒｎａ組成物及び方法
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
NO961536L (no) 1996-06-18
SK49796A3 (en) 1997-05-07
KR960705575A (ko) 1996-11-08
HU9601013D0 (en) 1996-06-28
BG100517A (bg) 1996-11-29
FI961681A0 (fi) 1996-04-17
WO1995011029A1 (en) 1995-04-27
CN1136278A (zh) 1996-11-20
NO961536D0 (no) 1996-04-18
HUT75224A (en) 1997-04-28
CA2173333A1 (en) 1995-04-27
LV11432A (lv) 1996-08-20
AU8083694A (en) 1995-05-08
EP0813414A1 (en) 1997-12-29
FI961681L (fi) 1996-06-12
PL314003A1 (en) 1996-08-05
LV11432B (en) 1996-12-20
EP0813414A4 (en) 1999-07-21
CZ109196A3 (en) 1996-10-16
JPH09504525A (ja) 1997-05-06
FI961681A7 (fi) 1996-06-12

Similar Documents

Publication Publication Date Title
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9406128A (pt) Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9400571A (pt) Processo para o tratamento de despejo orgânico
BR9407799A (pt) Composição de matéria método de tratamento e composição farmaceutica
BR9405911A (pt) Processo para a preparaçao de uma composiçao de copolímero em bloco e composiçao de copolímero em bloco
BR9504072A (pt) Composiçao farmacêutica métodos para o tratamento de hipercolesterolemia de aterosclerose e kit
FI962559A7 (fi) Hormonaaliseen raskauden ehkäisyyn ja/tai aknen hoitoon tarkoitettu lääke ja menetelmä
BR9406566A (pt) Composição farmacêutica uso de progesterona e/ou 17 - - estradiol e processo para a fabricação de uma preparação farmacêutica
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
PT936859E (pt) Composicao e metodo para o tratamento de plantas com quimicos exogenos
BR9204375A (pt) Composicao e processo para o tratamento de agua de refrigeracao
BR9203707A (pt) Compostos,composicao,emprego de compostos,processo para a fotopolimerizacao de compostos e emprego de uma composicao
BR9405216A (pt) Processo para preparação de uma alcanona e/ou um alcanol
FI951856A7 (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR8901135A (pt) Composicao para condicionamento de tecido e processo para tratar tecidos
BR9602337A (pt) Composto processo para sua preparação usos do mesmo processo para tratamento de arritmias e medicamento
BR9002081A (pt) Processo e aparelho para o tratamento de detritos organicos
BR9400338A (pt) Processo para preparação de 1,1,1,2-tetrafluoro-2-cloroetano e de pentafluoretano
BR9612206A (pt) Composto uso do composto composição farmacêutica processo para preparação do composto e para o tratamento da dor
BR9606925A (pt) Utilização de compostos e processo para o tratamento e profilaxia da obesidade
BR9205493A (pt) Composicao farmaceutica e processo para fabricacao de composicao farmaceutica

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal